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the substrate binding P-site of SYK [15, 16] Unlike available inhibitors of SYK that target the ATP binding site, C61 targets the tyrosine kinase substrate-binding site of SYK. C61 thereby provides a unique opportunity to selectively target the SYK-dependent anti-apoptotic survival machinery in leukemic B-cell precursors [15] . Notably, in vitro disruption of the SYK-STAT3 network with C61 augmented oxidative stress-induced apoptosis of primary leukemic cells from relapsed B-precursor ALL patients [15] .
By "decorating" nanoscale liposomal nanoparticles carrying C61 as the payload with PEGylated anti-CD19 monoclonal antibody (Ab) molecules, we developed a multifunctional LNP formulation of C61.
This C61-LNP-Ab provides a unique nanoscale CD19-specific pharmaceutical composition for therapeutic application against CD19-receptor positive B-precursor ALL. The purpose of the present study was to characterize this formulation and evaluate its anti-leukemic potency against primary leukemia cells from B-precursor ALL patients. We demonstrate that C61-LNP-Ab is more potent than untargeted C61-LNP and consistently causes apoptosis in radiation-resistant primary human Bprecursor ALL cells. C61-LNP-Ab was also capable of destroying B-precursor ALL xenograft cells and their leukemia-initiating in vivo clonogenic fraction. This unique pharmaceutical composition targeting the SYK-dependent anti-apoptotic blast cell survival machinery may be useful in overcoming the clinical radiochemotherapy resistance of B-precursor ALL cells.
Materials and Methods

1,4-Bis(9-O-dihydroquinidinyl) phthalazine/hydroquinidine 1,4-phathalazinediyl diether (C61)
and its nanoscale liposomal formulation. C61 is a potent and selective chemical inhibitor of SYK [15, 16] . Dipalmitoyl phosphatidylcholine (DPPC), cholesterol (CHOL), and 1,2-dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP) were obtained from Avanti Polar Lipids (Alabaster, AL). LBA and sucrose were obtained from Sigma (St Louis, MO). DSPE-PEG3400-NHS (the N-succinimidyl derivative of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3400] ("DSPE-PEG3400-NHS") was obtained from Nanocs, Inc.
(New York, NY). PD-10 desalting columns packed with Sephadex G-25 medium were obtained from
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Integrative Biology Accepted Manuscript GE Healthcare (Piscataway, NJ). The liposomal C61 nanoparticle formulation, C61-LNP, was prepared via the standard thin film evaporation method [17] in a round bottom flask using a fixed 26.2:13.8:3.0 ratio of DPPC: CHOL: DOTAP. The chloroform used in the LNP formulation was removed using a rotary evaporator at 40 o C. Entrapment of C61 was obtained using the pH gradient procedure with 0.3 M lactobionic acid (LBA) as a low pH buffer inside the LNPs. The LBA solution was added to the LNP film and the film was hydrated slowly with gentle hand mixing or by rocking the flask at ambient temperature for about 1 hour or until all the film was dispersed to yield a milky suspension. In order to obtain a nano-sized homogeneous LNP formulation, the suspension was placed in the chamber of an extruder, and extrusion was performed at 60 o C, twice through a 0.2 µm, then 5 times through a 0.1 µm polycarbonate filter. To establish a pH gradient, the external phase of the extruded preparation was passed through a PD-10 desalting column packed with Sephadex G-25 medium, which had been pre-equilibrated with 10% sucrose in water. After this external phase replacement step, C61 was added and the preparation was stirred at room temperature for 60 min to allow C61 to cross into the acidic interior of the LNPs. After the completion of the drug addition, the pH was adjusted upward to about 6.5 by the addition of sodium hydroxide solution. In the final step, the C61-LNP formulation was filter sterilized through 0.22 µm filters and stored in a 4 o C refrigerator.
We decorated C61-LNP with an in-house prepared anti-CD19 mouse monoclonal antibody (MoAb) (IgG2a) secreted by the hybridoma cell line ARESX1 developed using previously published standard methods [18] . To determine the unique cDNA sequence of the complementarity determining regions (CDR) of this MoAb, mRNA was extracted from around 10 7 ARESX1 hybridoma cells using Qiagen
Oligotex mRNA Mini kit (Cat. No70022). The first-strand cDNA was generated with oligo (dT) primers using Superscript III reverse transcriptase (Invitrogen, San Diego, CA Unreacted DSPE-PEG-NHS and small molecular weight reaction products were removed by passing the mixture through a pre-packed PD-10 size exclusion column (GE Healthcare Life Sciences, Piscataway, NJ) equilibrated in PBS (10 mM sodium phosphate, 138 mM NaCl, 2.7 mM KCl), pH 6.5. The fractions containing the majority of the MoAb were combined, concentrated, and mixed with C61-loaded C61-LNP according to a standard post-insertion procedure. This mixture was rotated in the controlled-temperature chamber at 45 o C for 6 h and then applied to a 1.6 x 40 cm Sephacryl S-300 HR size-exclusion column to separate the antibody-decorated C61-LNP (C61-LNPAb) from uninserted, modified anti-CD19 MoAb. The column was equilibrated in PBS, pH 7.4, at a flow rate of 0.5 mL/min. The optical density of the fractions eluting approximately 40 min after loading was followed at 600 nm. These fractions contained C61-LNP-Ab and were very cloudy and white. When the readings at 600 nm approached baseline, the OD was read at 280 nm to monitor the elution of the uninserted MoAb. The peak of antibody typically eluted between 70 and 80 min after loading. Size measurement by the dynamic light scattering (DLS) technique, Zeta potential measurements, analytical high performance liquid chromatography (HPLC) and transmission electron microscopy (TEM) were used for physicochemical characterization of the C61-LNP-Ab. We 
Transmission Electron Microscopy (TEM).
The morphology of the C61-LNP-Ab was examined using TEM, as previously described [17] . In brief, samples of liposomal nanoparticle formulations were diluted 1:1 with 2% uranyl acetate and placed on Formvar-coated copper grids (300 Mesh) for 5 min. The samples were then gently blotted against clean filter paper and air dried for 10 min. Grids were examined on a JEOL JEM-2100 LaB6 (Peabody, MA) transmission electron microscope and photographed with the Orius SC1000B Gatan (Pleasanton, CA) digital camera. Pairwise Two-sample Student's T-tests for differences between means were performed to assess the significance of the differences in percent viability of leukemic cells post-treatment between C61-LNP-Ab treatments vs. controls/non-leukemic mice as well as treatments with unmodified C61-LNP.
P-values of less than 0.05 were deemed significant and not corrected for multiple comparisons as the false discovery rate was less than 5% for the planned limited number of comparisons that were performed. compared to control, P = 0.0044 compared to Radiation alone, P=0.6 compared to non-leukemic controls) and 1.6 ± 0.1 cm ("not enlarged") for the C61-LNP-Ab + radiation group (N=5; P-value <0.0001 compared to control, P = 0.0029 compared to radiation alone, P=0.4 compared to nonleukemic controls) ( Figure 8C ). The average spleen nucleated cell count (in millions) as a measure of the leukemic burden was 598 ± 195 ("very high"; log 10 = 2.68 ± 0.15) for the control group (N=5), 17 ± 6 ("normal", log 10 = 1.17 ± 0.17; P-value = 0.0008 compared to control, P=0.2 compared to nonleukemic controls) for C61-LNP-Ab alone, and 8 ± 2 ("normal"; log 10 = 0.86 ± 0.10; P-value < 0.0001 compared to control; P-value = 0.0046 compared to radiation alone, P=0.5 compared to nonleukemic controls) for the combined C61-LNP-Ab + radiation group ( Figure 8D ). These findings demonstrate that C61-LNP-Ab alone or in combination with low dose radiation damages the in vivo clonogenic fraction in xenograft cell populations derived from patients with aggressive B-precursor ALL and abrogates their ability to engraft and cause overt leukemia in NOD/SCID mice.
SCID Mouse Xenograft Model of
Discussion
Liposomal nanoparticle therapeutics containing cytotoxic agents may provide the foundation for potentially more effective and less toxic anti-cancer treatment strategies due to their improved pharmacokinetics, reduced systemic toxicity, and increased intra-tumoral/intra-cellular delivery [21] [22] [23] . Nanoparticles can be functionalized with a tumor targeting moiety, such as a ligand or an antibody directed against a surface receptor on cancer cells in order to achieve optimal tumor targeting and site-specific drug delivery to further reduce their toxicity and improve their efficacy [24] [25] [26] [27] [28] . When linked with tumor targeting moieties nanoparticles can reach cancer cells carrying the target receptors with high affinity and precision [24] [25] [26] [27] [28] . The targeting ligands enable nanoparticles to bind to cell surface receptors and enter cells by receptor-mediated endocytosis [28] .
CD19 is a B-lineage specific 95 kDa surface receptor, which is expressed on leukemia cells from 85% of patients with ALL (100% of patients with B-precursor ALL), but is absent on the parenchymal cells of life-maintaining non-hematopoietic organs, circulating blood myeloid and erythroid cells, Tcells as well as bone marrow stem cells [20, 29, 30] . CD19 is found on the surface of each leukemic B-precursor ALL blast cell at a high density (>50,000 molecules/cell), shows a high affinity for native and engineered recombinant anti-CD19 MoAb/antibody fragments (K a >10 8 M -1 ), undergoes antibody induced internalization upon binding of anti-CD19 MoAb, and it is not shed from the surface [20, [29] [30] [31] . CD19 has also been found on in vivo clonogenic B-precursor ALL cells with leukemia initiating and propagating properties in xenograft models using immunocompromised mice [32] [33] [34] . The favorable leukemic cell vs. normal tissue expression profile of CD19 and its abundant expression on relapse B-precursor ALL clones make it an attractive molecular target for biotherapy in relapsed B-precursor ALL using anti-CD19 immunoconjugates [35, 36] , bispecific T-cell engaging antibodies [37] as well as targeted T-cell therapy using autologous T cells expressing a CD19-specific chimeric antigen receptor (CAR) [38] . We postulate that the nanotechnology-enabled delivery of C61 to leukemia cells will require lower systemic exposure levels for therapeutic efficacy and thereby significantly broaden the therapeutic window of this promising new anti-leukemia agent. We recently reported that a non-targeted nanoscale liposomal formulation of C61 had a very favorable safety profile in mice and exhibited potent anti-leukemic activity at nontoxic dose levels [17] . Therefore, we are optimistic that C61-LNP-Ab will also exhibit very favorable pharmacodynamics features in preclinical animal models.
MoAb and their fragments can cause potentially life-threatening immunotoxicity, including cytokine storms, anaphylaxis and anaphylactoid reactions, as well as autoimmunity. C61-LNP-Ab should be considered a partially MoAb-based therapeutic that could also cause similar side effects in clinical settings. Therefore, it will be important to carefully examine its potential immunotoxicological effects Control; P=0.54 vs. Non-Leukemic) for the C61-LNP-Ab + radiation group, and 4.6±0.4 ("normal"; log 10 = 0.65±0.04; P-value < 0.0001 vs Control) for the non-leukemic mice. D5W = water with 5% dextrose
